Oncotherapeutics clinical trials
The registry lists 22 studies whose lead sponsor is Oncotherapeutics. 5 are recruiting or about to start. Per ClinicalTrials.gov, last updated Jan 16, 2025.
Our grouping of 1 registry name, not the registry’s. See them and correct one ↓
- 22studies on the registry
- 5open to participants now
- 1reach primary completion within a year
Get an email when these change. Save the Oncotherapeutics studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
What it is testing
The drugs Oncotherapeutics’ studies test, most open studies first — 20 drugs with a page of their own. Each count opens the studies in search.
Open now Not open: under way, finished or stopped
- 2 open · 3
- 2 open · 2
- 2 open · 2
- 1 open · 1
- 1 open · 1
- 0 open · 4
- 0 open · 4
- 0 open · 4
- 0 open · 3
- 0 open · 3
Show 10 moreShow fewer
Coming up
1 of Oncotherapeutics’ studies under way reach primary completion within a year. The dates are the sponsor’s own estimates, which often move.
Phase 3 Other phases
- NNov ’26’26
- DDec
- JJan ’27’27
- FFeb
- MMar
- 1AApr
- MMay
- JJun
- JJul
- AAug
- SSep
- OOct
- NNov
The study
- Apr 2027A Trial of Selinexor, Ruxolitinib and Methylprednisoloneselinexor, ruxolitinib · NCT06225310
Add it to your calendar (.ics) → With an account.
All 22 at a glance
Where each study is in its life, its phase and its countries. Each count opens them in search.
Over the years
- 08
- 09
- 10
- 11
- 312
- 13
- 14
- 15
- 16
- 17
- 18
- 19
- 20
- 21
- 22
- 23
- 24
- 25
- 026
By the year each study started; 2 started before 2008. 2026 so far in the lighter column.
Registry sponsor names on this page
Our grouping. This page groups the registry's lead sponsor names by company — our grouping, not the registry's. It can be wrong or incomplete: an acquired company whose name never mentions its owner may be missing. Use “Something wrong?” under any name below to correct it.
Tell us about a missing company
Each name exactly as ClinicalTrials.gov lists it, and how it relates to Oncotherapeutics.
- Oncotherapeutics22 studiesSame company
Something wrong?
Focus areas
Conditions Oncotherapeutics leads ten or more studies in, by study count. A broader condition is left out when almost all its studies are already in a narrower one listed here.
Studies
Recruiting first, then most recently updated. Showing 22 of 22.
- A Study of Venetoclax in Combination With Isatuximab and Dexamethasone for Relapsed/Refractory Multiple MyelomaRecruitingNCT06115135Phase 2
- A Trial of Selinexor, Ruxolitinib and MethylprednisoloneRecruitingNCT06225310Phase 1
- Pilot Study Using Changes in Serum BCMA to Determine Disease Progression in Multiple MyelomaRecruitingNCT06209606Early Phase 1
- A Phase 1 Study of Ruxolitinib, Steroids and Lenalidomide for Relapsed/Refractory Multiple Myeloma (RRMM) PatientsRecruitingNCT03110822Phase 1
- Selinexor Treatment for Multiple Myeloma Patients Who Are Refractory to Lenalidomide-containing Therapy.RecruitingNCT04519476Phase 1
- Pomalidomide for Lenalidomide for Relapsed or Refractory Multiple Myeloma PatientsTerminatedNCT02188368Phase 2
- Weekly 70 mg/m2 Carfilzomib for Multiple Myeloma Patients Refractory to 27 mg/m2 CarfilzomibTerminatedNCT02294357Phase 2
- Ixazomib as a Replacement for Carfilzomib and Bortezomib for Multiple Myeloma PatientsCompletedNCT02206425Phase 1/2
- Ph 2 Maintenance Trial: Ixazomib vs Ixazomib-Lenalidomide for MM PatientsTerminatedNCT03733691Phase 2
- Combination Study for High Risk Multiple Myeloma PatientsTerminatedNCT03104270Phase 2
- Serum Vitamin D Levels and Peripheral Neuropathy Among Multiple Myeloma PatientsCompletedNCT01697839
- Safety, Efficacy, and Pharmacodynamics of a 60-Minute Infusion of Carfilzomib for Progressive Multiple MyelomaStatus unknownNCT01792102Phase 1/2
- Study of Carfilzomib for Multiple Myeloma Patients Who Are Relapsed/Refractory to Bortezomib-containing TreatmentsCompletedNCT01365559Phase 1/2
- Subcutaneous (SC) Bortezomib-Regimens for Patients With RR MM Failing Prior IV Bortezomib-Containing RegimensTerminatedNCT01695330Phase 2
- Pomalidomide, Dexamethasone and Pegylated Liposomal Doxorubicin for Relapsed/Refractory Multiple MyelomaStatus unknownNCT01541332Phase 1/2
- Pegylated Liposomal Doxorubicin, Bortezomib, Dexamethasone and Lenalidomide for Relapsed/Refractory Multiple MyelomaCompletedNCT01160484Phase 2
- A Study of the Effectiveness of Armodafinil to Treat Cancer-Related Fatigue in Patients With Multiple MyelomaCompletedNCT01160380Phase 3
- Melphalan and Panobinostat (LBH589) for the Treatment of Patients With Recurrent Multiple MyelomaCompletedNCT00743288Phase 1/2
- Doxorubicin Hydrochloride Liposome, Bortezomib, and Dexamethasone in Treating Patients With Newly Diagnosed Multiple MyelomaStatus unknownNCT00742404Phase 2
- Bortezomib, Ascorbic Acid, and Melphalan in Treating Patients With Newly Diagnosed Multiple MyelomaCompletedNCT00317811Phase 2
- Samarium 153 and Bortezomib in Treating Patients With Relapsed or Refractory Multiple MyelomaCompletedNCT00316940Phase 1
- Melphalan, Arsenic Trioxide, and Ascorbic Acid in Treating Patients With Relapsed or Refractory Multiple MyelomaWithdrawnNCT00085345Phase 2